Open AccessA Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder
Author(s) -
Azmi Nasser,
Tesfaye Liranso,
Toyin Adewole,
Nicholas Fry,
Joseph T. Hull,
Gregory D. Busse,
Fatima Chowdhry,
Andrew J. Cutler,
Nandita Joshi Jones,
Robert L. Findling,
Stefan Schwabe
Publication year - 2021
Publication title -
journal of clinical psychopharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.786
H-Index - 121
eISSN - 1533-712X
pISSN - 0271-0749
DOI - 10.1097/jcp.0000000000001404
Subject(s) - placebo , attention deficit hyperactivity disorder , medicine , placebo controlled study , extended release , randomized controlled trial , psychiatry , psychology , pharmacology , double blind , alternative medicine , pathology
This phase 3 clinical trial evaluated the efficacy and safety of viloxazine extended-release capsules (VLX-ER) as a monotherapy for attention-deficit/hyperactivity disorder (ADHD) in adolescents (12-17 years).